Please login to the form below

Not currently logged in
Email:
Password:

Xtandi

This page shows the latest Xtandi news and features for those working in and with pharma, biotech and healthcare.

Bayer, Orion prep challenge in prostate cancer market

Bayer, Orion prep challenge in prostate cancer market

Astellas said in its latest results statement that Xtandi made around $2.2bn in the first nine months of fiscal 2018/19, while J&J banked around $3.5bn from Zytiga ... Pfizer and Astellas have just reported positive results from the ARCHES trial of

Latest news

More from news
Approximately 28 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Analysts believe the drug could achieve peak sales of around $1.7bn, but will face fierce competition from the likes of Pfizer and Astellas’ established Xtandi. ... It also gives J&J a leg-up in what looks set to be a big market tussle with Pfizer and

  • Deal Watch August 2016 Deal Watch August 2016

    35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

  • Deal Watch May 2016 Deal Watch May 2016

    The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already

  • Deal Watch March 2016 Deal Watch March 2016

    Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.

  • Astellas: Ten years young Astellas: Ten years young

    Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide). ... There it is currently conducting a series of investigations in breast cancer to assess

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

  • Astellas makes senior EMEA appointments Astellas makes senior EMEA appointments

    Both men are veterans of Astellas. Dew joined the company in 2006 as senior manager business development and has worked on major products such as Xtandi.

  • Astellas poaches new oncology head from Takeda Astellas poaches new oncology head from Takeda

    She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics